Back to results
US 5,180,831 AGranted
Quaternary pyridinium compounds
AssigneeGeorgia Tech Research Corporation
InventorsJames C. Powers, Sheldon W. May, Maria A. Hernandez, Steve Thornton, Jan Glinski
Life of this patent
Estimating the term…
Abstract
Quaternary pyridinium compounds, their use in inhibiting acetylcholinesterase, their roles in the prophylaxis and treatment of organophosphate poisoning, their roles in anticholinesterase therapy and their roles as agents mimicking or opposing the actions of the natural neurotransmitter acetylcholine.
Claims3
A compound of the group consisting of the formulas:
- ##STR12## and any counterion to make pharmaceutically acceptable salts, wherein Z is selected from the group consisting of C.sub.1-6 alkyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached naphthyl group, C.sub.1-6 alkyl with two attached phenyl groups, C.sub.1-6 alkyl with an attached phenyl group mono, di or trisubstituted with J, C.sub.1-6 alkyl with two attached phenyl groups mono, di or trisubstituted with J, C.sub.1-6 alkyl with an attached naphthyl group mono, di, or trisubstituted with J,
- wherein J is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylamine, C.sub.1-6, alkyl-O-CO-, C.sub.1-6 alkyl-O-CO-NH-, C.sub.1-6 alkyl-NH--CO--NH-, C.sub.1-6 alkyl-NH--CO--O--, C.sub.1-6 aklyl NH--CO--, (C.sub.1-6 alkyl).sub.2 N-CO-,
- wherein X is selected from the group consisting of OH, C.sub.1-6 alkyl-NH--CO--O--,(C.sub.1-6 alkyl).sub.2 -N--CO--O, C.sub.1-6 fluoroalkyl-NH--CO--O, (C.sub.1-6 fluoroalkyl).sub.2 -NH--CO--O,
- Y is O or S,
- wherein R.sub.2 is selected from the group consisting of H, C.sub.1-6 alkyl, phenyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached phenyl group mono, di, or trisubstituted with K, C.sub.1-6 alkyl with an attached naphthyl group, C.sub.1-6 alkyl with an attached naphthyl group mono, di, or trisubstituted with K,
- wherein R.sub.3 is selected from the group consisting of H, C.sub.1-6 alkyl, phenyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached phenyl group mono, di or trisubstituted with K,
- wherein K is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylamine, C.sub.1-6 alkyl-O-CO-, C.sub.1-6 alkyl-O-CO-NH-, C.sub.1-6 alkyl-NH--CO--NH--, C.sub.1-6 alkyl-NH--CO--O--, C.sub.1-6 alkyl NH--CO--, (C.sub.1-6 alkyl).sub.2 N-CO-,
- wherein B is selected from the group consisting of H, C.sub.1-6 alkyl.
5 more elements
A compound of the group consisting of the formulas:
- ##STR13## with any counterion to make pharmaceutically acceptable salts, wherein X.sub.1 is selected from the group consisting of H, OH, C.sub.1-6 alkyl-NH--CO--O--, (C.sub.1-6 alkyl).sub.2 -N--CO--O--, C.sub.1-6 fluoroalkyl-NH--CO--O--, (C.sub.1-6 fluoroalkyl).sub.2 -NH--CO--O--,
- Y is O or S,
- Z is selected from the group consisting of C.sub.1-6 alkyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached naphthyl group, C.sub.1-6 alkyl with two attached phenyl groups, C.sub.1-6 alkyl with an attached phenyl group mono, di or trisubstituted with J, C.sub.1-6 alkyl with two attached phenyl groups mono, di or trisubstituted with J, C.sub.1-6 alkyl with an attached naphthyl group mono, di, or trisubstituted with J,
- wherein J is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylamine, C.sub.1-6 alkyl-O-CO-, C.sub.1-6 alkyl-O--CO--NH--, C.sub.1-6 alkyl-NH--CO--NH--, C.sub.1-6 alkyl-NH--CO--O--, C.sub.1-6 alkyl NH--CO--, (C.sub.1-6 alkyl).sub.2 N-CO-,
- wherein R.sub.4 is selected from the group consisting of C.sub.1-6 alkyl with a pyridinium ring attached through nitrogen, C.sub.1-6 alkyl with a pyridinium ring attached through nitrogen and mono, di, or trisubstituted with K, C.sub.1-6 alkyl with a quinolinium ring attached through nitrogen and mono, di, or trisubstituted with K, C.sub.1-6 alkyl with an isoquinolinium ring attached through nitrogen and mono, di, or trisubstituted with K, C.sub.1-6 alkyl-T,
- wherein T is selected from the group consisting of formula (I) and formula (II), ##STR14## wherein R', R", and R"' are selected from the group consisting of H, C.sub.1-6 alkyl, C.sub.1-6 fluoroalkyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached phenyl group mono, di, or trisubstituted with K, C.sub.1-6 fluoroalkyl with an attached phenyl group mono, di, or trisubstituted with K,
- wherein K is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-6 alkoxy, C.sub.1-6 alkylamine, C.sub.1-6 alkyl-O-CO-, C.sub.1-6 alkyl-O-CO-NH, C.sub.1-6 alkyl -NH--CO--NH-, C.sub.1-6 alkyl-NH-CO-O-, C.sub.1-6 alkyl NH-CO-, (C.sub.1-6 alkyl).sub.2 N-CO,
- wherein B is selected from the group consisting of H, C.sub.1-6 alkyl.
5 more elements
A compound of the formula:
- ##STR15## with any counterion to make pharmaceutically acceptable salts, wherein Y is O or S,
- Z is selected from the group consisting of C.sub.1-6 alkyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached naphthyl group, C.sub.1-6 alkyl with two attached phenyl groups, C.sub.1-6 alkyl with an attached phenyl group mono, di, or trisubstituted with J, C.sub.1-6 alkyl with two attached phenyl groups mono, dis or trisubstituted with J, C.sub.1-6 alkyl with an attached naphthyl group mono, di, or trisubstituted with J,
- wherein J is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylamine, C.sub.1-6 alkyl-O--CO--, C.sub.1-6 alkyl-O--CO--NH--, C.sub.1-6 alkyl-NH--CO--NH--, C.sub.1-6 alkyl -NH--CO--O--, C.sub.1-6 alkyl NH--CO--, (C.sub.1-6 alkyl).sub.2 N-CO-,
- R.sub.7 is selected from the group consisting of C.sub.1-6 alkyl, phenyl, C.sub.1-6 alkyl with an attached phenyl group, C.sub.1-6 alkyl with an attached phenyl group mono, di, or trisubstituted with K, C.sub.1-6 alkyl with an attached naphthyl group, C.sub.1-6 alkyl with an attached naphthyl group mono, di, or trisubstituted with K,
- wherein R.sub.8 is selected from the group consisting of C.sub.1-6 alkyl, phenyl, C.sub.1-6 with an attached phenyl group, C.sub.1-6 alkyl with an attached phenyl group mono, di, or trisubstituted with K,
- wherein K is selected from the group consisting of halogen, COOH, OH, CN, NO.sub.2, NH.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylamine, C.sub.1-6 alkyl-O-CO-, C.sub.1-6 alkyl-O-CO-NH-, C.sub.1-6 alkyl-NH--CO--NH--, C.sub.1-6 alkyl-NH--CO--O, C.sub.1-6 alkyl NH--CO--, (C.sub.1-6 alkyl).sub.2 N-CO-.
3 more elements
Dependencies are inferred from the claim text.